Analysts at Oppenheimer recently upgraded the medtech company Intuitive Surgical (ISRG) from "Perform" to "Outperform" and set a $500 price target, implying a 24.6% upside from current levels. Expecting the company to benefit from the growth in robotic surgery, Oppenheimer analysts expect Intuitive to maintain a leading position in the market despite increasing competition. Intuitive also has a vision regarding the usage of artificial intelligence (AI) in such surgeries, helping medical personnel achieve better outcomes.
The company is developing AI as a capability stack that leverages real-world surgical data to build advanced vision-language and reasoning models capable of answering complex surgical questions. A $210 Billion Reason to Buy AMD Stock Here CoreWeave vs Nebius: Both Companies Reported Strong Earnings, But Here's the Stock You Should Buy As Oracle Deepens Its Partnership with AWS, Here's How You Should Play ORCL Stock Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know.
Intuitive Surgical is a global medical technology company that designs, manufactures, and markets robotic-assisted surgical systems, instruments, and accessories for minimally invasive procedures. Headquartered in Sunnyvale, California, its core platform is the da Vinci Surgical System, complemented by the Ion endoluminal system for diagnostic lung biopsies. Intuitive has a market capitalization of $141.76 billion.
Expectations surrounding the stock have cooled while its valuation remains rich. Additional headwinds include concerns that could reduce elective surgery volumes, a lingering product recall of certain da Vinci components, and rising competition. Over the past 52 weeks, Intuitive's stock has dropped 16.8%, while it is down 29.15% year-to-date (YTD).
The stock reached a 52-week low of $328.57 on July 23, but is up 22.13% from that level. On a forward-adjusted basis, Intuitive's price-to-earnings (non-GAAP) ratio of 37.18 times is higher than the industry average of 19.60 times. For the second quarter, Intuitive's revenue increased 18.5% year-over-year (YOY) to $2.89 billion, which is higher than the $2.82 billion that Wall Street analysts had expected.
The majority of the top line came from instrument and accessory sales, which climbed 17.7% YOY to $1.73 billion. Moreover, the revenue surge was driven by solid volume expansion. Globally, combined da Vinci and Ion procedures rose about 16% YOY in the second quarter, with da Vinci up roughly 15% and Ion surging around 36%.
Extract — continue reading at the source.
